Modality
siRNA
MOA
HER2
Target
CD123
Pathway
Cell Cycle
CML
Development Pipeline
Preclinical
~Feb 2019
→ ~May 2020
Phase 1
Aug 2020
→ Jan 2031
Phase 1Current
NCT06386057
2,338 pts·CML
2020-08→2031-01·Terminated
2,338 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-01-214.8y awayPh2 Data· CML
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1/2
Termina…
Catalysts
Ph2 Data
2031-01-21 · 4.8y away
CML
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06386057 | Phase 1/2 | CML | Terminated | 2338 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A | |
| MRU-8112 | Merus | Preclinical | PD-L1 |